Reuters logo
10 个月前
BRIEF-FDA concludes Xarelto clinical trial results not affected by Alere's INRatio
2016年10月11日 / 下午4点41分 / 10 个月前

BRIEF-FDA concludes Xarelto clinical trial results not affected by Alere's INRatio

Oct 11 (Reuters) - U.S. FDA:

* Analyses conclude that Xarelto clinical trial results were not affected by Alere's faulty monitoring device INRatio

* FDA concludes blood thinner drug Xarelto is a safe and effective alternative to warfarin in patients with atrial fibrillation Source text bit.ly/2e3iYqp Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below